Fulgent Genetics, Inc. (FLGT)

The past six months have seen several events impacting Fulgent Genetics' stock price. Fulgent reported its fourth-quarter and full-year 2025 financial results, which included lower-than-expected guidance for 2026, causing the stock price to decline. Fulgent Genetics completed the acquisition of Bako Diagnostics and StrataDx on March 17, 2026. The company announced its third-quarter 2025 financial results, reporting revenue growth and raised its full-year 2025 revenue guidance. Several analysts downgraded Fulgent Genetics' stock or lowered their price targets following the Q4 2025 earnings report and revised 2026 guidance.

Explicit information regarding the demand seasonality for Fulgent Genetics' core genetic testing products and services is not detailed in the provided search results. The company's revenue dependence on COVID-19 testing has significantly decreased, indicating that the surge in demand for those specific tests during the pandemic was event-driven rather than a recurring seasonal pattern.

Fulgent Genetics, Inc. is a technology company focused on providing comprehensive genetic testing services to physicians, offering clinically actionable diagnostic information to enhance patient care. The company operates within the Healthcare sector and the Diagnostics & Research industry. Fulgent Genetics offers a broad range of genetic tests, including single-gene tests and multi-gene panels for various genetic conditions, genomic testing, hereditary cancer and tumor profiling, carrier screening, prenatal testing, pharmacogenetic testing, anatomic pathology, sequencing services, at-home genetic testing, and COVID-19 testing. Beyond its laboratory services, Fulgent Genetics also has a therapeutic development business focused on developing drug candidates for various cancers.

Fulgent Genetics, Inc. is headquartered in El Monte, California, U.S. The vast majority of its revenue is generated from the United States, with additional operations in foreign markets. The company has expanded its geographic reach and laboratory presence through acquisitions, adding CLIA, CAP, and NY State certified laboratories in New York, Arizona, Massachusetts, and Texas.

Fulgent Genetics' brand reputation has faced challenges in the past year, particularly in early 2026. A legal investigation was initiated by Kirby McInerney LLP concerning potential violations of federal securities laws. This investigation followed a substantial drop in the company's stock price after Fulgent reported lower-than-expected Q4 and full-year 2025 financial results and reduced 2026 guidance, leading to increased competitive pressure and undermined investor confidence, negatively affecting the company's market reputation. Analyst downgrades also reflect a more cautious view of the company.

Fulgent Genetics is primarily owned by institutional shareholders and company insiders, with a small percentage held by retail investors. Major Institutional Owners include BlackRock, Inc., Vanguard Group Inc, and Acadian Asset Management Llc. The largest individual shareholder is Hsieh Trust Ming, followed by Ming Hsieh, the CEO and Chairman.